Producing treatment hierarchies in network meta-analysis using probabilistic models and treatment-choice criteria

Theodoros Evrenoglou¹, Adriani Nikolakopoulou^{1,2}, Guido Schwarzer¹, Gerta Rücker¹, Anna Chaimani³

^{1:} Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center-University of Freiburg, Freiburg im Breisgau, Germany

^{2:} Department of Hygiene, Social-Preventive Medicine and Medical Statistics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

^{3:} Université Paris Cité, Center of Research in Epidemiology and Statistics, Inserm, Paris, France

Corresponding author: Dr. Theodoros Evrenoglou

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University

of Freiburg, Freiburg im Breisgau, Germany

email: theodoros.evrenoglou@uniklinik-freiburg.de

Abstract

A key output of network meta-analysis (NMA) is the relative ranking of the treatments; nevertheless, it has attracted a lot of criticism. This is mainly due to the fact that ranking is an influential output and prone to over-interpretations even when relative effects imply small differences between treatments. To date, common ranking methods rely on metrics that lack a straightforward interpretation, while it is still unclear how to measure their uncertainty. We introduce a novel framework for estimating treatment hierarchies in NMA. At first, we formulate a mathematical expression that defines a treatment choice criterion (TCC) based on clinically important values. This TCC is applied to the study treatment effects to generate paired data indicating treatment preferences or ties. Then, we synthesize the paired data across studies using an extension of the so-called 'Bradley-Terry' model. We assign to each treatment a latent variable interpreted as the treatment's 'ability' and we estimate the ability parameters within a regression model. Higher ability estimates correspond to higher positions in the final ranking. We further extend our model to adjust for covariates that may affect treatment selection. We illustrate the proposed approach and compare it with alternatives in two datasets: a network comparing 18 antidepressants for major depression and a network comparing 6 antihypertensives for the incidence of diabetes. Our approach provides a robust and interpretable treatment hierarchy which accounts for clinically important values and is presented alongside with uncertainty measures. Overall, the proposed framework offers a novel approach for ranking in NMA based on concrete criteria and preserves from over-interpretation of unimportant differences between treatments.

Keywords: network of interventions, treatment hierarchy, probabilistic regression model, clinically important difference

1 Introduction

Interpretation of network meta-analysis (NMA) outputs can be challenging as it usually comprises consideration of multiple treatment effects with different levels of uncertainty and credibility across comparisons in networks^{1,2}. For example, in the relatively simple case of a network with 6 treatments the output of NMA consists of 15 unique treatment effect estimates. In such a context, treatment ranking can be a reliable way to summarize the evidence provided by a complex network of treatments^{1,3,4}. This may explain the fact that treatment hierarchies are frequently presented in published NMAs with 43% of them reporting at least one ranking metric⁵.

Probably the most commonly used ranking metric, until recently, was the probability of a treatment to have the best value⁶, usually denoted as p_{BV} . It can be calculated within either the Bayesian or the frequentist framework and represents the probability that a treatment in the network will have the best mean value on the studied outcome⁷. Although p_{BV} has been widely used in published NMAs, more recently it has been criticized for not accounting properly for the uncertainty of the NMA estimates^{4,8,9}. This is because a treatment may have a high probability of producing both the best and the worst mean outcome⁷.

Other common ranking metrics are P-scores⁴, which are obtained analytically through the cumulative density function of the standard normal distribution, or their Bayesian equivalent SUCRA¹ that represent the surface under the cumulative ranking curve for each treatment. The main limitation of these metrics is that the scores attributed to the treatments often lead to attributing distinct ranks to treatments even when there are only small differences between their scores. Nikolakopoulou et al.⁸ employed the "deviation from the means" approach for the construction of the design matrix¹⁰ in the NMA model and introduced a new ranking metric, called the probability of a treatment being preferable to a fictional treatment of average performance (PReTA). This metric also accounts better for the uncertainty in the relative effects than P-scores or SUCRAs, particularly when there is substantial variability in the precision of the NMA estimates. This is an important advantage since an empirical study revealed high agreement across all ranking metrics when NMA estimates had similar variance of the NMA estimates⁶. More recently, new ranking metrics and approaches have been developed to address more complex ranking questions. Mavridis et al.¹¹ extended P-scores to incorporate multiple outcomes and

clinically important values. Chaimani et al.¹² suggested that treatment rankings should not only consider the summary relative effects and introduced a new metric, called the probability of selecting a treatment to recommend (POST-R) that implements additional characteristics in treatment hierarchy (e.g. risk of bias or treatment cost). Finally, Tervonen et al.¹³ applied multiple-criteria decision analysis for treatment ranking and Papakonstantinou et al.¹⁴ developed a resampling approach for estimating the probability that a specific treatment hierarchy may occur.

Despite its usefulness when properly reported and interpreted, ranking in NMA has been accompanied with a lot of skepticism^{15–17}. Common arguments against treatment ranking include that it can be biased it is difficult to interpret, and it is not accompanied with uncertainty measures^{16–18}. However, Salanti et al.⁷ argued that these criticisms should not refer to the ranking metrics per se but to the way they are used and interpreted. This is because different metrics target different types of hierarchy questions and researchers should clearly define what they mean by "best treatment" in a given setting. Hence, setting a well-defined treatment hierarchy question should always precede the estimation of treatment ranking and drive the choice of the ranking metric⁷.

Although the aforementioned recent ranking approaches may improve to some degree the limitations of the more traditional metrics, such as p_{BV} , P-score and SUCRA, none of them can address all the criticism points jointly. In this article, we introduce a novel approach for estimating treatment hierarchies in NMA using a probabilistic model that allows synthesizing study-level paired preference data. First, we formulate a mathematical expression that defines a treatment choice criterion (TCC) based on clinically important values. We then apply the criterion to the study-level relative treatments effects, taking into account their confidence intervals and produce paired data indicating either a treatment preference or a tie for each study-specific pairwise comparison. Our synthesis model estimates the treatment hierarchy through a latent parameter assigned to each treatment in the network that represents its 'ability'. In this way, treatments with higher estimated abilities are positioned more prominently in the final ranking. This modeling approach has been previously widely used to produce rankings in fields outside of medicine, such as sports science¹⁹, animal behavior²⁰, risk analysis²¹, and educational assessment²². The proposed approach connects ranking with a population parameter, therefore naturally allows for the presentation of treatment ranking alongside with uncertainty measures. We further provide an

extension of the proposed approach that accounts for study-level covariates to provide insight about into the robustness of the ranking when different study characteristics, such as the risk of bias (RoB), are taken into account. To illustrate our method and compare it with existing alternatives we use two real-life published NMAs: one comparing different antidepressants²³ for major depression and a second evaluating different antihypertensives²⁴ for the incidence of diabetes.

2 Methods

2.1 General setting

Suppose a network of *N* studies comparing *T* treatments in total, with the number of treatments in study *i* denoted by T_i . Let y_i be the vector of all the treatment effects in study *i*. The elements of the vector y_i are denoted with $y_{i,XY}$ and represent the treatment effects for the comparison between any treatments *Y* and *X* of study i = 1, 2, ..., N. Following the "reduce-weights" approach proposed by Rücker et al.^{25,26}, we assume that the length of the vector y_i is equal to $\binom{T_i}{2}$. This implies that the variances of the treatment effects from multi-arm studies are inflated to capture the dependencies that exist among the $\binom{T_i}{2}$ treatments effects in these studies²⁷. Finally, each element of the vector y_i is associated with a (usually 95%) confidence/credible interval with lower and upper bounds l_i and u_i and elements $l_{i,XY}$ and $u_{i,XY}$ respectively.

2.2 Defining treatment choice criteria

We start building our modeling approach by defining concrete criteria for choosing one treatment over another or considering two treatments as equivalent. These criteria may depend on several factors, such as the clinical setting, the outcome(s) under investigation, or even the type of patients under consideration (e.g. chronic patients vs treatment-naïve individuals). Here, we suggest a generic approach that can be easily adapted to different settings based on the so-called range of equivalence (ROE). The ROE has been previously introduced as a way to infer on the clinical significance of a treatment effect in the context of appraising NMA results; relative effects lying within this range are considered lacking clinical significance²⁸.

Following Nikolakopoulou et al.²⁸, we construct the ROE using the minimal clinically important difference (MCID). For a study-specific pairwise comparison between treatments Y and X to indicate a treatment preference, the relative treatment effect must be outside the ROE. The

treatment preference (i.e., Y > X or X > Y) is then determined based on the direction of the treatment effect, favoring either Y or X, and the length of its confidence interval, which should indicate a statistically significant effect with at least one bound outside the ROE. Otherwise, the treatments are considered as equivalent (i.e. X = Y). To mathematically represent this rule suppose that $I_{i,XY}^{(1)}$ and $I_{i,XY}^{(2)}$ are two indicator variables defined for each pairwise comparison XY in study i = 1, 2, ..., N as

$$I_{i,XY}^{(1)} = \begin{cases} 1, & \text{if } (l_{i,XY} > U^{\text{LOE}}) \text{ or } \left[\left(y_{i,XY} > U^{\text{LOE}} \right) \text{ and } \left(l_{i,XY} > q_0 \right) \right] \\ 0, \text{ otherwise} \end{cases}$$
(1)

and

$$I_{i,XY}^{(2)} = \begin{cases} -1, & \text{if } (u_{i,XY} < L^{\text{LOE}}) \text{ or } \left[\left(y_{i,XY} < L^{\text{LOE}} \right) \text{ and } \left(u_{i,XY} < q_0 \right) \right] \\ 0, \text{ otherwise} \end{cases}$$
(2)

where L^{LOE} and U^{LOE} are the lower and upper limits of the ROE respectively, and q_0 is the null effect. Then, the TCC for each comparison *XY* of study *i* can be defined for a beneficial outcome based on the following conditions:

$$Y > X, if \sum_{k=1}^{2} I_{i,XY}^{(k)} = 1$$
(3a)

$$X > Y$$
, if $\sum_{k=1}^{2} I_{i,XY}^{(k)} = -1$ (3b)

$$Y = X$$
, if $\sum_{k=1}^{2} I_{i,XY}^{(k)} = 0$ (3c)

where Y > X or X > Y indicate a treatment preference and Y = X indicates a 'tie' (i.e. treatment equivalence). In case of a harmful outcome, we need to reverse the signs of 1 and -1 in Equations (3a) and (3b). A graphical illustration of the above TCC for the case of a beneficial outcome is given in. A graphical illustration of the above TCC for the case of a beneficial outcome is given in **Figure 1.** Approaches for defining a MCID have been suggested elsewhere and are beyond the scope of this article^{29,30}. Investigators that would prefer to use a different TCC can modify Equations (1) and (2) accordingly.



Figure 1: A graphical representation of the TCC for a fictional example comparing treatments Y and X in terms of a beneficial outcome.

After defining the TCC, we transform the study-level data from relative effect estimates into wins for each comparison XY and study i = 1, 2, ..., N. Treatment preference data from multi-arm studies are grouped together to retain the total number of degrees of freedom in the network³¹.

2.3 Estimating treatment hierarchies using probabilistic models

To synthesize the resulting study-level treatment preference data, we adapt the so-called 'Bradley-Terry model'^{32,33} to the context of NMA. This is a probabilistic ranking model originally suggested to model outcomes in other fields of research^{19–22} but to our knowledge never used to estimate treatment hierarchies. We parameterize the model using an unobserved latent parameter $\psi_X \ge 0$ that represents the 'true absolute ability' each treatment X = 1, 2, ..., T has to beat the other treatments in the network. In this way, treatments with higher estimated ability occupy a higher position in the final ranking list³⁴. The idea behind this model stems from Luce's axiom^{34–36} of choice which states that the probability for choosing a treatment X from a finite set of treatments

T is equal to $\frac{\psi_X}{\sum_{t\in T}\psi_t}$.

2.3.1 Synthesizing treatment preference data in the absence of ties

Following the above axiom, for each pairwise comparison in the network the probability that treatment X will be preferred over treatment Y ($X \neq Y$; X, Y, = 1,2, ..., T) is,

$$\Pr(X > Y) = \frac{\psi_X}{\psi_X + \psi_Y} \tag{4}$$

with $\psi_X \ge 0 \ \forall X \in \{1, 2, ..., T\}$ and $\sum_{X=1}^T \psi_X = 1$. Based on Equation (4) a logit-linear model can be parametrized as

$$logit(\Pr(X > Y)) = \log(\psi_X) - \log(\psi_Y)$$
(5)

The parameter estimation for the above model relies on maximum likelihood theory^{32,33,37}. Let r_{XY} denote the number of times that treatment X is preferred to treatment Y across their total m_{XY} direct comparisons in the studies of the network. Then, the log-likelihood function across all available comparisons in the network is

$$L(\boldsymbol{\psi}) = \sum_{k < q} \sum_{r_{XY}} \log\left(\frac{\psi_X}{\psi_X + \psi_Y}\right) + (m_{XY} - r_{XY}) \log\left(\frac{\psi_Y}{\psi_X + \psi_Y}\right)$$
(6)

Maximizing the binomial log-likelihood in Equation (6) results in the maximum likelihood estimates (MLE) of the log-ability parameters and consequently to the MLEs $\hat{\psi}_X, \forall X \in \{1, 2, ..., T\}$ of the ability parameters by exponentiating the logarithms.

Equation (4) assumes that one treatment is always preferred over another for any pairwise comparison in the network. However, this can violate the TCC defined in section 2.2 where we also consider that two treatments may be clinically equivalent. Therefore, an extension to this ranking model is necessary to allow incorporating ties between treatments.

2.3.2 Synthesizing treatment preference data including ties

Following Davidson³⁸, we assume that the probability of a tie between two treatments X and Y is proportional to $\nu \sqrt{\psi_X \psi_Y}$. The quantity $\sqrt{\psi_X \psi_Y}$ is the geometric mean of ψ_X and ψ_Y , while ν is a scalar nuisance parameter that controls for the prevalence of ties in the network. Hence, the probability of preferring X over Y is now

$$\Pr(X > Y) = \frac{\psi_X}{\psi_X + \psi_Y + \nu \sqrt{\psi_X \psi_Y}}$$
(7)

and the probability that the two treatments are equivalent is

$$\Pr(X = Y) = \frac{\nu \sqrt{\psi_X \psi_Y}}{\psi_X + \psi_Y + \nu \sqrt{\psi_X \psi_Y}}$$
(8)

with $\psi_X \ge 0, \forall X \in \{1, 2, ..., T\}, \nu > 0$ and $\sum_{X=1}^T \psi_X = 1$. Considering Equations (7) and (8), the log-likelihood in Equation (6) becomes

$$L^*(\boldsymbol{\psi}, \boldsymbol{\nu}) = \frac{1}{2} \sum_{X < Y} 2r_{XY} \log\left(\frac{\psi_X}{\psi_X + \psi_Y + \nu\sqrt{\psi_X\psi_Y}}\right) + w_{XY} \log\left(\frac{\nu\sqrt{\psi_X\psi_Y}}{\psi_X + \psi_Y + \nu\sqrt{\psi_X\psi_Y}}\right)$$
(9)

where w_{XY} is the number of ties between treatments X and Y. Maximization of the multinomial log-likelihood in Equation (9) relies on iterative optimization processes such as the Newton-Raphson³⁸ or the minorization-maximization³⁷ algorithms and results in the MLEs of the ability parameters ψ and the scalar parameter ν that represents the prevalence of ties. The asymptotic distribution of $\hat{\psi}$ is a multivariate normal distribution with mean ψ and variance-covariance matrix Σ^{-1} obtained as the inverse of the Hessian matrix Σ . The elements of Σ correspond to the second partial derivatives of the log-likelihood in Equation (9). Based on the asymptotic theory, the standard errors of the elements of $\hat{\psi}$ are derived as the square roots of the diagonal elements of matrix Σ^{-1} . Finally, a unique and positive MLE for each $\psi_X, X \in \{1, 2, ..., T\}$ exists under Ford's regularity condition³⁹. This requires that for every possible partition of the treatments into two non-empty subsets, some treatments in the second subset are preferred to some treatments in the first subset at least once. In other words, if only ties are obtained from the TCC, it is not meaningful to estimate any treatment hierarchy.

2.3.3 Absolute and relative treatment abilities

The maximization of Equation (9) in terms of $\boldsymbol{\psi}$ refers to an optimization problem constrained at the region { $\psi_X \ge 0$, $\sum_{X=1}^T \psi_X = 1$ }. This constrain prevents from negative estimates of the ability parameters and guarantees that the optimization problem remains identifiable. Then, the resulting $\hat{\psi}_X$ represent the estimated absolute abilities of each treatment in the network. Note that the final estimates $\hat{\psi}_X$ do not necessarily satisfy $\sum_{X=1}^T \psi_X = 1$ as the re-normalization of the vector $\boldsymbol{\psi}$ is not needed after each iteration of the iterative process³⁷. However, re-normalizing the final MLEs as $\hat{\pi}_X = \frac{\hat{\psi}_X}{\sum_{X=1}^T \hat{\psi}_X}$ allows interpreting each $\hat{\pi}_X$ as the probability that each treatment $X \in \{1, 2, ..., T\}$ is the best (in terms of the TCC used) among all the other alternatives³¹.

If relative treatment abilities are of interest, they can be obtained by replacing the constrain $\sum_{X=1}^{T} \psi_X = 1$ with arbitrarily setting the ability of a treatment $X_0 \in \{1, 2, ..., T\}$ equal to 0. In this case the problem remains identifiable but the resulting T - 1 estimates will represent the relative

abilities of each treatment $X \neq Y$ in the network versus the reference treatment X_0 . The remaining $\binom{T}{2} - (T-1)$ relative ability estimates can be obtained as linear combinations of the T-1 basic estimates, as the MLEs of the model follow the consistency equations as in a typical NMA. Alternatively, we can construct an artificial reference treatment group³¹ T + 1 with ability equal to the average of the absolute ability estimates across all the T treatments. This means that we assume the true ability of the treatment T + 1 being equal to $\psi_{T+1} = \frac{\sum_{X=1}^{T} \hat{\psi}_X}{T}$. Then, the ranking results are presented in terms of the ability ratios $\frac{\hat{\psi}_X}{\psi_{T+1}} \forall X \in \{1, 2, ..., T\}$.

2.3.4 Accounting for study-level covariates

Similar to treatment effects, treatment abilities can vary between subgroups of studies with different characteristics such as risk of bias, study duration, etc. To take these characteristics into account in the ranking model, we use a semi-parametric approach that allows to automatically specify subgroups with significantly different sets of ability parameters. This approach recursively partitions the covariate space between groups of studies with different characteristics and provides the final ranking within these subgroups through the following process⁴⁰:

- Fit the ranking model to the treatment preference data obtained after applying the pre-defined TTC to the studies of the network.
- 2) Assess the stability of the ability estimates with respect to each available covariate. The term stability here indicates that there are no significant shifts in the treatment abilities based on the studied covariates. Following Strobl et al.⁴⁰, for categorical covariates with Q categories the stability assessment of the ability estimates relies on a χ^2 -test statistic with T(Q 1) degrees of freedom. For continuous covariates the limiting distribution of the test statistic is the supremum of a tied-down Bessel process⁴⁰.
- 3) If there is a significant instability (i.e. an important shift in the treatment abilities), split the full data by the l^{th} covariate with the strongest instability, using the cut-off point that gives the highest improvement in model fit. Suppose that the l^{th} continuous covariate has been chosen to split and let c_{il} denote the value of the l^{th} covariate in study i = 1, 2, ..., N. Then, to identify which subgroups of the l^{th} covariate result into different ranking lists, an optimal cut-off point ξ needs to be specified. This specification relies on the maximization of the partitioned log-likelihood defined across all studies with covariate value lower than ξ and across all studies with covariate values larger that ξ . Let $M(\xi) = \{c_{il} \in \mathbb{R}: c_{il} \leq \xi\}$ be the set of all studies

where the covariate has value lower or equal to ξ . Let also $N(\xi) = \{c_{il} \in \mathbb{R} : c_{il} > \xi\}$ be the set of all studies where the covariate has value greater than ξ . Then the optimal cut-off point ξ is the value that maximizes the partitioned likelihood function⁴⁰ defined as $L^*(\widehat{\psi}^{(M(\xi))}, \widehat{v}) + L^*(\widehat{\psi}^{(N(\xi))}, \widehat{v})$, where $L^*(\cdot)$ is the log-likelihood defined in Equation (9). The cut-off point ξ represents the value between which we observe the largest shift in at least one ability estimate $\widehat{\psi}_X$ over the range of values of c_{il} . For categorical variables there is no need for an optimal cut-off point to be specified. The Q categories can be partitioned into any two subgroups and the chosen partition will again be the one that maximizes the partitioned likelihood.

4) Repeat steps 1-3 for each subgroup until there are no more significant instabilities. The order according to which the covariates are chosen for splitting depends on the p-value of the statistical test; the covariate with the smallest p-value is the one that will be split first.

Note that for small networks or networks with high prevalence of ties identifying optimal subgroups can be challenging. In such cases, splitting into subgroups will most probably result into an underpowered analysis within the sets M and N. Therefore, it is very likely that the ranking list obtained from the global analysis will not be altered across any potential partition of c_{il} .

3 Applications

We illustrate the use of our novel method and compare it with existing ranking approaches using two published networks. The first compares the efficacy of several antidepressants for major depression²³ and the second compares different antihypertensive drug classes and placebo for the incidence of diabetes²⁴. We compared five ranking approaches: (1) P-scores obtained from a random or common-effects NMA model⁴, (2) P-scores 'adjusted' for the MCID¹¹, (3) the PReTA-ranking⁸, (4) the ranking according to p_{BV} , and (5) the estimated treatment abilities from our novel ranking approach.

3.1 Antidepressants for major depression

This network comprises 179 trials comparing 18 antidepressant drugs (**Figure 2a**). The primary outcome is response to treatment defined as a 50% or greater reduction in a depression symptom scale between baseline and 8 weeks of follow-up. The outcome is measured with odds ratios (OR).



Figure 2: Network plots for the two clinical examples. Panel (a) shows the network of antidepressants while panel (b) the network of antihypertensives. Abbreviations for panel (b), ACE: angiotensin-converting-enzyme inhibitors, ARB: angiotensin-receptor blockers, CCB: calcium-channel blocker, BBlocker: Beta Blocker.

The results for methods (1) to (4) are presented in **Table 1**. A consensus is observed in terms of the best treatment for the P-scores and the p_{BV} which rank vortioxetine at the first position while using PReTA-ranking vortioxetine is placed at the second position. However, these high positions of vortioxetine in the ranking list may be somewhat over-optimistic given that it is the least studied antidepressant in the entire network and, thus, there is increased uncertainty about its performance. Specifically, vortioxetine is directly compared with venlafaxine only, through only one study in the network. The NMA estimates for this network are shown in **Figure 3**. Overall, all NMA estimates appear to be on the direction favoring vortioxetine but with large CIs. Interestingly, the NMA estimate for the comparison of venlafaxine against vortioxetine is less precise compared to the respective single direct estimate which is equal to 0.72 with a CI ranging from to 0.49 to 1.05. This is because the variance of the NMA estimate is inflated due to heterogeneity while not indirectly informed by any other comparison in the network. When using p_{BV} , the ranking does not account for the uncertainty in treatment effects, which explains why vortioxetine appears to be the best treatment.

Table 1: Ranking metrics for the network of antidepressants and ranks according to each ranking metric in parentheses. With bold the treatments that are in the first three positions in the ranking list in each ranking metric.

Treatment	P-scores (random)	P-scores (common)	P-scores with CIV (random)	PReTA	$p_{\scriptscriptstyle BV}$	$\widehat{\pi}_X$
vortioxetine	0.90 (1)	0.94 (1)	0.75 (1)	0.93 (2)	0.63 (1)	0.05 (9)
escitalopram	0.83 (2)	0.86 (2)	0.49 (3)	0.98 (1)	0.08 (3)	0.18 (2)
bupropion	0.79 (3)	0.81 (3)	0.53 (2)	0.87 (5)	0.19 (2)	0.21 (1)
mirtazapine	0.75 (4)	0.78 (4)	0.39 (4)	0.91 (3)	0.04 (4)	0.10 (3)
amitriptyline	0.71 (5)	0.75 (5)	0.33 (5)	0.88 (4)	0.01 (5-7)	0.05 (5)
agomelatine	0.64 (6)	0.59 (7)	0.29 (6)	0.74 (8)	0.01 (5-7)	0.05 (8)
paroxetine	0.62 (7)	0.61 (6)	0.25 (8)	0.83 (6)	0.00 (8-18)	0.05 (7)
venlafaxine	0.61 (8)	0.59 (8)	0.25 (7)	0.78 (7)	0.00 (8-18)	0.07 (4)
duloxetine	0.52 (9)	0.49 (9)	0.21 (9)	0.53 (9)	0.00 (8-18)	0.02 (15)
milnacipran	0.49 (10)	0.47 (11)	0.19 (10)	0.46 (10)	0.01 (5-7)	0.03 (12)
sertraline	0.45 (11)	0.48 (10)	0.15 (12)	0.38 (11)	0.00 (8-18)	0.05 (6)
nefazodone	0.38 (12)	0.39 (12)	0.16 (11)	0.33 (12)	0.01 (5-7)	0.03 (11)
citalopram	0.37 (13)	0.35 (13)	0.12 (13)	0.24 (13)	0.00 (8-18)	0.04 (10)
clomipramine	0.26 (14)	0.28 (14)	0.07 (14)	0.10 (14)	0.00 (8-18)	0.02 (14)
fluvoxamine	0.25 (15)	0.25 (15)	0.07 (15)	0.10 (15)	0.00 (8-18)	0.01 (17)
fluoxetine	0.23 (16)	0.22 (16)	0.06 (16)	0.01 (18)	0.00 (8-18)	0.02 (13)
trazodone	0.12 (17)	0.09 (18)	0.03 (17)	0.02 (16)	0.00 (8-18)	0.01 (16)
reboxetine	0.09 (18)	0.04 (17)	0.02 (18)	0.02 (17)	0.00 (8-18)	0.01 (18)

Following the original publication²³, we assume an MCID equal to 1.20. Using MCID adjusted P-scores, vortioxetine was ranked again at the top position and clearly higher than bupropion which is at the second position. The differences between unadjusted and MCID adjusted P-scores can be attributed to the increased emphasis that the latter approach puts on the magnitude of the NMA estimates. Overall, the differences across the different hierarchies may be explained by the substantial variation of the standard errors across the NMA estimates. Notably, the range of standard errors from 0.07 to 0.33 is very wide. The full distribution of the standard errors across all NMA estimates is depicted in Appendix Figure 1a.



Figure 3: Forest plots showing the summary odds ratios obtained from the antidepressants network assuming vortioxetine as the reference treatment group.

Setting again an MCID=1.20, we obtain the respective ROE that lies from 0.85 to 1.20. Then, we applied the TCC of **Section 2.2** to transform the study relative effects into treatment preference data. We illustrate this procedure in Appendix Figure 2 using as an example the 10 studies that compare escitalopram vs citalopram. Overall, a high prevalence of ties exists in the network as 165 of 185 study-specific relative effects do not result in a treatment preference. The final ability estimates are shown in **Figure 4**. Bupropion and escitalopram are the two treatments with the largest abilities; the former has a slightly larger ability in magnitude but the latter is more precise. Vortioxetine is now ranked in the middle with a very wide confidence interval that reveals the uncertainty around this treatment. The tie prevalence estimate \hat{v} is 10.31. Although not directly interpretable, one can use this estimate alongside with the ability estimates and calculate the probability of a tie between two treatments (Equations (7), (8)). For example, the probability that escitalopram and bupropion have equal abilities is 86%, which reveals important uncertainty around the first position in the treatment ranking. The normalized abilities $\hat{\pi}_X$ interpreted as the probability that each treatment is at the first position are shown in **Table 1**. Overall, due to the high prevalence of ties in the network the overall ranking is very uncertain as all probabilities are

very small while the probabilities related to the first two treatments are only 21% and 18% for bupropion and escitalopram, respectively.



Figure 4: Ranking results obtained using the proposed methodology for the antidepressants example.

We also investigated the impact of study characteristics on the final ranking. Following the original publication²³, we considered the following potential modifiers of the treatment abilities: mean age of study participants, study RoB, study duration, publication year, and mean baseline risk. The results showed that the treatment ranking remained robust across levels of these covariates as we did not identify any important subgroups within which the ranking changed.

3.2 Antihypertensives and the incident of diabetes

This network consists of 22 trials comparing 5 classes of antihypertensive treatments and placebo for the incidence of diabetes²⁴. This is a very well-connected network with 14 out of the possible 15 direct comparisons being observed (**Figure 2b**). The primary outcome is the proportion of patients who developed diabetes and the NMA estimates using Placebo as reference can be found in Appendix Figure 3.

We consider again an MCID equal to 1.20^{41} and the respective ROE ranging from 0.83 to 1.20. The ranking results obtained from the approaches (1) to (4) can be found in **Table 2** and the results

Treatment	P-scores (random)	P-scores (common)	P-scores with CIV (random)	PReTA	p_{BV}	$\widehat{\pi}_X$
ARB	0.95 (1)	0.99 (1)	0.67 (1)	1.00 (1-2)	0.78 (1)	0.81 (1)
ACE	0.84 (2)	0.81 (2)	0.52 (2)	1.00 (1-2)	0.21 (2)	0.12 (2)
Placebo	0.55 (3)	0.51 (3)	0.32 (3)	0.77 (3)	0.00 (3-6)	0.04 (3)
CCB	0.46 (4)	0.49 (4)	0.24 (4)	0.45 (4)	0.00 (3-6)	0.02 (4)
BBlocker	0.16 (5)	0.17 (5)	0.02 (5)	0.00 (5)	0.00 (5-6)	0.01 (5)
Diuretic	0.04 (6)	0.03 (6)	0.00 (6)	0.00 (6)	0.00 (5-6)	0.00 (6)

Table 2: Ranking metrics for the network of the antihypertensive drugs and ranks according to each ranking metric in parentheses.

in terms of the estimated treatment abilities are depicted in **Figure 5**. Here, there is complete agreement in the final ranking across all five approaches with ARB always placed at the first position. According to the probabilities $\hat{\pi}_X$, ARB is overall the best treatment with probability of 81%. The large precision around the best treatment can also be attributed to the small rate of ties



Figure 5: Ranking results obtained using the proposed methodology for the antihypertensives example.

obtained from the TCC at the study level. Specifically, out of 30 study-specific treatment effects in total, 43% of them show a clear treatment preference. Overall, the perfect agreement across the different ranking methods, in this example, can be probably attributed also to lack of substantial

uncertainty in the treatment effect estimates. Specifically, the standard errors of the NMA estimates range from 0.07 to 0.10 (Appendix Figure 1b).

4 Discussion

In this paper, we introduce a novel framework for producing treatment hierarchies in NMA through a probabilistic model. We start by transforming the study-level relative effects into treatment preferences (wins) or treatment equalities (ties) for each pairwise contrast based on a pre-defined TCC. We propose as a clinically relevant TCC the ROE between two treatments that represents the area within which their relative effect lacks clinical significance^{28,41}. Following previous work, we define the ROE using the MCID and its reciprocal (or opposite) value^{28,41}. Then, we parametrize our model to estimate the ability of each treatment to be preferred over the other treatments in the network^{32,34,38}; that is a latent characteristic that determines the final ranking with larger ability estimates corresponding to higher positions. We further incorporate study-level covariates that may affect treatment abilities and assess the robustness of the estimated hierarchy.

We used two published networks to assess the properties of our method and compare it with existing approaches. In the network of antidepressants²³, our approach appeared more conservative with respect to under-studied treatments that exhibit large but imprecise treatment effects. Specifically, vortioxetine, which was evaluated in a single study only, was ranked first using P-scores or p_{BV} and third using PReTA, but was placed in the middle of the ranking with a highly uncertain ability estimate using our novel approach. In the second network of antihypertensives²⁴ we found a perfect agreement in the final ranking across all approaches. This is probably due to absence of large differences in the precision of the estimated NMA relative effects and the low rate of ties obtained at the study level by our TCC.

We see several advantages of our proposed treatment ranking approach. First, the requirement of to a priori define a concrete TCC forces researchers to consider early on what constitutes a preferred treatment. In the new approach we conceptualize the treatment ability as a population parameter which is a key difference to previous ranking approaches (i.e. P-scores, SUCRA, PReTA, p_{BV})⁹, we conceptualize the treatment ability as a population parameter. This allows us to obtain the standard error of the estimated abilities and to infer the uncertainty of ranking positions using standard statistical measures. In addition, the proposed model does not provide treatment

ability estimates when all or the majority of study-level contrasts indicate ties due to convergence failure. Although this might be considered as a drawback of the model, we see it as an advantage as it prevents researchers from making ranking statements in the absence of sufficient treatment effect precision. This is in line with previous NMA recommendations for avoiding the presentation of ranking results in the presence of large uncertainty in the relative effects⁶. Finally, the proposed approach can also account for study-level covariates through the semi-parametric model-partitioning method^{31,40}.

Despite these advantages, our approach is not free of limitations. Probably the most important limitation is that the definition of the MCID and of the respective ROE involves some subjectivity²⁹. On the other hand, though, the use of different ROEs allows researchers to estimate the treatment hierarchy under different settings (e.g. for different patient profiles). Ways to mitigate this inherent subjectivity have been suggested in the literature through fully statistical approaches²⁵ or by incorporating information from patients⁴². Moreover, investigators conducting NMAs may choose to define another TCC not based on the ROE. To avoid data-driven decisions, we recommend meta-analysts using our ranking method to define and justify the TCC they plan to use in their protocol. Our approach might be less beneficial over existing ranking approaches in well-connected networks where there is not large variation in the precision of the relative effect estimates. That was apparent in the antihypertensives network where the estimated ranking was the same irrespective of the approach used.

Our proposed framework offers a novel alternative to existing ranking metrics for estimating treatment hierarchies in NMA. The importance of a well-defined treatment hierarchy question prior to estimating treatment ranking has been highlighted recently⁷. To our knowledge, this is the first approach that incorporates explicitly and quantitatively considerations on the treatment hierarchy question through the pre-defined TCC. At the same time, it allows assessing the robustness of the ranking results when incorporating multiple covariates. Future extensions of the proposed approach will include accounting for multiple outcomes. Overall, investigators can use the proposed approach either as their primary ranking tool or as sensitivity analysis alongside conventional ranking metrics particularly for networks with increased uncertainty in their relative effects and knowledge of clinically relevant TCC.

References

- 1. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol*. 2011;64(2):163-171. doi:10.1016/j.jclinepi.2010.03.016
- 2. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. *PloS one*. 2013;8(10):e76654.
- Chaimani A, Caldwell DM, Li T, Higgins JP, Salanti G. Undertaking network meta-analyses. In: *Cochrane Handbook for Systematic Reviews of Interventions*. John Wiley & Sons, Ltd; 2019:285-320. doi:10.1002/9781119536604.ch11
- 4. Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC medical research methodology*. 2015;15(1):58.
- 5. Petropoulou M, Nikolakopoulou A, Veroniki AA, et al. Bibliographic study showed improving statistical methodology of network meta-analyses published between 1999 and 2015. *J Clin Epidemiol.* 2017;82:20-28. doi:10.1016/j.jclinepi.2016.11.002
- Chiocchia V, Nikolakopoulou A, Papakonstantinou T, Egger M, Salanti G. Agreement between ranking metrics in network meta-analysis: an empirical study. *BMJ Open*. 2020;10(8):e037744. doi:10.1136/bmjopen-2020-037744
- Salanti G, Nikolakopoulou A, Efthimiou O, Mavridis D, Egger M, White IR. Introducing the Treatment Hierarchy Question in Network Meta-Analysis. *Am J Epidemiol*. 2022;191(5):930-938. doi:10.1093/aje/kwab278
- Nikolakopoulou A, Mavridis D, Chiocchia V, Papakonstantinou T, Furukawa TA, Salanti G. Network meta-analysis results against a fictional treatment of average performance: Treatment effects and ranking metric. *Research Synthesis Methods*. 2021;12(2):161-175. doi:10.1002/jrsm.1463
- 9. Veroniki AA, Straus SE, Rücker G, Tricco AC. Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis? *J Clin Epidemiol*. 2018;100:122-129. doi:10.1016/j.jclinepi.2018.02.009
- 10. Hosmer D. Interpretation of the fitted logistic regression model. *Applied logistic regression*. 2000;2:47.
- 11. Mavridis D, Porcher R, Nikolakopoulou A, Salanti G, Ravaud P. Extensions of the probabilistic ranking metrics of competing treatments in network meta-analysis to reflect clinically important relative differences on many outcomes. *Biometrical Journal*. 2020;62(2):375-385. doi:10.1002/bimj.201900026

- 12. Chaimani A, Porcher R, Sbidian É, Mavridis D. A Markov chain approach for ranking treatments in network meta-analysis. *Statistics in Medicine*. 2021;40(2):451-464. doi:10.1002/sim.8784
- 13. Tervonen T, Naci H, van Valkenhoef G, et al. Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention. *Med Decis Making*. 2015;35(7):859-871. doi:10.1177/0272989X15587005
- 14. Papakonstantinou T, Salanti G, Mavridis D, Rücker G, Schwarzer G, Nikolakopoulou A. Answering complex hierarchy questions in network meta-analysis. *BMC Medical Research Methodology*. 2022;22(1):47. doi:10.1186/s12874-021-01488-3
- 15. Mills EJ, Kanters S, Thorlund K, Chaimani A, Veroniki AA, Ioannidis JPA. The effects of excluding treatments from network meta-analyses: survey. *BMJ*. 2013;347. doi:10.1136/bmj.f5195
- 16. Trinquart L, Attiche N, Bafeta A, Porcher R, Ravaud P. Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials. *Ann Intern Med.* 2016;164(10):666-673. doi:10.7326/M15-2521
- Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and Technical Challenges in Network Meta-analysis. *Ann Intern Med.* 2013;159(2):130-137. doi:10.7326/0003-4819-159-2-201307160-00008
- 18. Kibret T, Richer D, Beyene J. Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study. *Clin Epidemiol*. 2014;6:451-460. doi:10.2147/CLEP.S69660
- 19. Cattelan M, Varin C, Firth D. Dynamic Bradley–Terry modelling of sports tournaments. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*. 2013;62(1):135-150. doi:https://doi.org/10.1111/j.1467-9876.2012.01046.x
- 20. Stuart-Fox DM, Firth D, Moussalli A, Whiting MJ. Multiple signals in chameleon contests: designing and analysing animal contests as a tournament. *Animal Behaviour*. 2006;71(6):1263-1271. doi:https://doi.org/10.1016/j.anbehav.2005.07.028
- 21. Merrick JRW, van Dorp JR, Mazzuchi T, Harrald JR, Spahn JE, Grabowski M. The Prince William Sound Risk Assessment. *Interfaces*. 2002;32(6):25-40. doi:10.1287/inte.32.6.25.6474
- 22. Pollitt A. The method of Adaptive Comparative Judgement. Assessment in Education: Principles, Policy & Practice. 2012;19(3):281-300. doi:10.1080/0969594X.2012.665354
- 23. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet.* 2018;391(10128):1357-1366. doi:10.1016/S0140-6736(17)32802-7

- 24. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet*. 2007;369(9557):201-207. doi:10.1016/S0140-6736(07)60108-1
- 25. Rücker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods*. 2012;3(4):312-324. doi:10.1002/jrsm.1058
- 26. Rücker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. *Stat Med.* 2014;33(25):4353-4369. doi:10.1002/sim.6236
- 27. Salanti G, Higgins JPT, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. *Stat Methods Med Res.* 2008;17(3):279-301. doi:10.1177/0962280207080643
- 28. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. *PLoS Med.* 2020;17(4):e1003082. doi:10.1371/journal.pmed.1003082
- 29. Copay AG, Subach BR, Glassman SD, Polly DWJ, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. *Spine J*. 2007;7(5):541-546. doi:10.1016/j.spinee.2007.01.008
- 30. McGlothlin AE, Lewis RJ. Minimal Clinically Important Difference: Defining What Really Matters to Patients. *JAMA*. 2014;312(13):1342-1343. doi:10.1001/jama.2014.13128
- 31. Turner HL, van Etten J, Firth D, Kosmidis I. Modelling rankings in R: the PlackettLuce package. *Computational Statistics*. 2020;35(3):1027-1057. doi:10.1007/s00180-020-00959-3
- 32. Bradley RA, Terry ME. Rank analysis of incomplete block designs: I. The method of paired comparisons. *Biometrika*. 1952;39(3/4):324-345.
- 33. Agresti A. Categorical Data Analysis. John Wiley & Sons; 2003.
- 34. Firth D, Kosmidis I, Turner H. Davidson-Luce model for multi-item choice with ties. *arXiv* preprint arXiv:190907123. Published online 2019.
- 35. Luce RD. Individual Choice Behavior: A Theoretical Analysis. New York: Wiley; 1959.
- 36. Luce RD. The choice axiom after twenty years. *Journal of mathematical psychology*. 1977;15(3):215-233.
- 37. Hunter DR. MM algorithms for generalized Bradley-Terry models. *The Annals of Statistics*. 2004;32(1):384-406, 23.
- 38. Davidson RR. On extending the Bradley-Terry model to accommodate ties in paired comparison experiments. *Journal of the American Statistical Association*. 1970;65(329):317-328.

- 39. Ford Jr LR. Solution of a ranking problem from binary comparisons. *The American Mathematical Monthly*. 1957;64(8P2):28-33.
- 40. Strobl C, Wickelmaier F, Zeileis A. Accounting for Individual Differences in Bradley-Terry Models by Means of Recursive Partitioning. *Journal of Educational and Behavioral Statistics*. 2011;36(2):135-153. doi:10.3102/1076998609359791
- Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: Software for semiautomated assessment of the confidence in the results of network metaanalysis. *Campbell Systematic Reviews*. 2020;16(1):e1080. doi:https://doi.org/10.1002/cl2.1080
- 42. Sahker E, Furukawa TA, Luo Y, et al. Estimating the smallest worthwhile difference of antidepressants: a cross-sectional survey. *BMJ Ment Health*. 2024;27(1). doi:10.1136/bmjment-2023-300919